Antibiotic treatment duration for patients with bloodstream infection: a systematic review and meta-analysis

Yuting Li (liyuting-86@163.com)  
The First Hospital of Jilin University

Juan Yang  
The First Hospital of Jilin University

Hongmei Yang  
The First Hospital of Jilin University

Jianxing Guo  
The First Hospital of Jilin University

Dong Zhang  
The First Hospital of Jilin University

Research

Keywords: Antibiotic treatment duration, optimal duration, bloodstream infection, bacteremia, short course, long course

DOI: https://doi.org/10.21203/rs.3.rs-106504/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Objectives: The optimal duration of therapy for primary bloodstream infection (BSI) and BSI secondary to major organ system infections has been poorly defined. A systematic review and meta-analysis was performed to evaluate the impact of short (≤10 days) and long course (>10 days) of antibiotic treatment on clinical outcomes in patients with BSI.

Methods: We searched the PubMed, Cochrane, and Embase databases for randomized controlled trials (RCTs) and cohort studies from inception to the 1st of October 2020. We included studies involving patients with BSI. All authors reported our primary outcome of all-cause mortality and clearly comparing short versus long course of antibiotic treatment with clinically relevant secondary outcomes (source control and relapse). Results were expressed as odds ratio (OR) with accompanying 95% confidence interval (CI).

Results: Six studies including 3593 patients were included. The primary outcome of this meta-analysis showed that there was no statistically significant difference in the all-cause mortality between two groups (OR=1.10; 95% CI, 0.82 to 1.48; P=0.52; Chi²=7.57; I²=34%). Secondary outcomes demonstrated that there was no statistically significant difference in the source control (OR=0.82; 95% CI, 0.61 to 1.10; P=0.18; Chi²=2.68; I²=25%) and relapse (OR=1.20; 95% CI, 0.71 to 2.01; P=0.49; Chi²=0.26; I²=0%) between two groups.

Conclusions: Short course of antibiotic treatment is not associated with either an increased risk of mortality or an increased odds of relapse compared with longer antibiotic treatment course for BSI. Furthermore, short course of antibiotic therapy is non-inferior to long course in terms of source control. Further large-scale RCTs are still required to confirm these results.

1. Introduction

Bloodstream infection (BSI) is defined by positive blood cultures in a patient with systemic signs of infection and may be either secondary to a documented source or primary—that is, without identified origin[1]. Timely administration of the appropriate antibiotic treatment remains the cornerstone for favorable clinical outcome in patients with BSI[2–4]. However, the optimal duration of therapy for primary BSI and BSI secondary to major organ system infections has been poorly defined[5]. Sufficient duration of antimicrobial therapy is required to prevent clinical failure and relapse. However, the risk of a longer antibiotic course may lead to Clostridium difficile infection, development of microbial resistance, potential need for central line access, venous thrombosis, line infection and bacteremia and increased cost[6].

A multicenter observational study of patients who have BSI in Canadian intensive care units (ICUs) suggests that most patients are treated with 2-week courses of antimicrobials, but with substantial practice heterogeneity among individual patients and with no clear relationship between duration of treatment and survival[7]. The current Infectious Diseases Society of America (IDSA) guidelines suggest that the duration of treatment for intravascular catheter related BSI should be between 7 and 14 days[8], but there is no consensus on the optimal duration of the antimicrobial therapy for non-catheter related BSI. The lack of data on the appropriate treatment duration for this subset of patient leads to uncertainty, usually resolved by prolonged treatment durations.

Since the optimal duration of the antibiotic treatment for patients with BSI remains unknown, we conducted a meta-analysis which extracted results from published studies to evaluate the impact of short and long course of antibiotic treatment on clinical outcomes in patients with BSI.

2. Methods

This systematic review and meta-analysis is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines[9]. Ethical approval was not necessary for this study because it was a review of the published literature.

2.1. Search strategy

We searched the PubMed, Cochrane, and Embase databases for studies from inception to the 1st of October 2020 using the following search terms: bloodstream infection, bacteremia, duration of treatment, antibiotic treatment duration, optimal duration, antibacterial treatment, antibiotics, antibacterial agents, short course, long course, sepsis. The search was slightly adjusted according to the requirements of the different databases. The authors' personal files and reference lists of relevant review articles were also reviewed. The flow chart of the search strategies is summarized in Fig. 1.

2.2. Types of outcome measures

The primary outcome was all-cause mortality, all-cause mortality included hospital mortality, 28-day mortality, 30-day mortality and 90-day mortality. Secondary outcomes were source control and relapse. Weighted means were calculated based on the number of patients in each study.

2.3. Study selection

The inclusion criteria were as follows: (1) RCTs as well as prospective and retrospective cohort studies; (2) patients with BSI; (3) all authors reported our primary outcome of all-cause mortality; (4) clearly comparing short (≤ 10 days) versus long course (> 10 days) of antibiotic treatment with clinically relevant secondary outcomes. We excluded studies that did not define the duration of treatment based on the 10-day limit and studies without clear comparisons of the outcomes. In addition, we excluded review articles and studies about pediatric.

2.4. Quality assessment
Two reviewers (YL and JY) independently performed quality assessment. The quality of studies was assessed using the Newcastle-Ottawa Scale (NOS) for cohort studies[10]. NOS allocates a maximum of 9 points according to the quality of the selection, comparability, and outcomes of the cohort study populations. Study quality was defined as poor (0–3), fair (4–6) or good (7–9). The quality of the included cohort studies is presented in Table 1.

### Table 1
Quality of the included cohort studies (The Newcastle-Ottawa Scale)

| Study            | Selection | Comparability | Outcome |
|------------------|-----------|---------------|---------|
|                  | Representativeness of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts on the basis of design or analysis | Assessment of outcome | Was follow-up long enough for outcomes to occur | Adequacy of follow-up of cohorts | Total Score |
| Havey 2013       |           |               |         |           |                           |                      |                       |                         |             | 8          |
| Nelson 2017      |           |               |         |           |                           |                      |                       |                         |             | 9          |
| Chotiprasit      |           |               |         |           |                           |                      |                       |                         |             | 9          |
| Sakul 2018       |           |               |         |           |                           |                      |                       |                         |             | 9          |
| Giannella 2018   |           |               |         |           |                           |                      |                       |                         |             | 9          |
| Sousa 2019       |           |               |         |           |                           |                      |                       |                         |             | 9          |
| Lee 2019         |           |               |         |           |                           |                      |                       |                         |             | 9          |

2.5. Statistical analysis

Statistical analyses were performed using Review Manager Version 5.3 (RevMan, The Cochrane Collaboration, Oxford, United Kingdom). Odds ratio (OR) with 95% confidence intervals (CI) was calculated for dichotomous variables. A random-effects model was used to pool studies with significant heterogeneity, as determined by the chi-squared test (P < 0.10) and inconsistency index (I² ≥ 50%)[11]. A P-value < 0.05 was set as the threshold of statistical significance.

3. Result

3.1. Study characteristics

The search strategy identified 1269 studies, and the data were from six cohort studies comprising 3593 patients (Table 2)[12–17]. The characteristics of the included studies are shown in Table 2. A total of six eligible studies were published between 2013 and 2019. Among these studies, two studies were conducted in USA, one study was conducted in Spain, one study was conducted in Colombia, one study was conducted in Canada and one study was conducted in China/Taiwan. Four of these studies were single-center studies and two were multicenter studies. The definitions of short and long course of antibiotic treatment in studies included in the meta-analysis are outlined in Table 3.
Table 2
The basic characteristics of studies included in meta-analysis

| Author [12] | Year | Country | Study period | All-cause mortality | Study design | No. of patients |
|-------------|------|---------|--------------|---------------------|--------------|----------------|
|             |      |         |              |                     |              | Total | Short course | Long course |
| Havey       | 2013 | Canada  | Mar.2010-Mar.2011 | Hospital            | Single center, retrospective cohort study | 72    | 19           | 53          |
| Nelson [13] | 2017 | USA     | Jan.2010-Dec.2013 | 90-day              | Multicenter, retrospective cohort study | 101   | 57           | 44          |
| Chotiprasitsakul [14] | 2018 | USA | 2008–2014 | 30-day | Multicenter, retrospective cohort study | 770  | 385          | 385         |
| Giannella [15] | 2018 | Colombia | Jan.2013-Dec.2016 | 28-day | Single center, retrospective cohort study | 856  | 426          | 430         |
| Sousa [16] | 2018 | Spain   | Oct.2015-Oct.2016 | 30-day | Single center, retrospective cohort study | 395  | 163          | 232         |
| Lee [17]    | 2018 | China/Taiwan | Jan.2007-Dec.2014 | 30-day | Single center, retrospective cohort study | 1089 | 726          | 363         |

Table 3
Definitions of short and long course of antibiotic treatment in studies included in the meta-analysis

| Study          | Short course | Long course |
|----------------|--------------|-------------|
| Havey 2013     | ≤10 days     | >10 days    |
| Nelson 2017    | 7–10 days    | >10 days    |
| Chotiprasitsakul 2018 | 6–10 days | 11–16 days |
| Giannella 2018 | ≤10 days     | >10 days    |
| Sousa 2019     | 7–10 days    | >10 days    |
| Lee 2019       | 5–10 days    | 11–16 days  |

3.2. Primary outcome
A total of six studies including 3593 patients were included, and the all-cause mortality was about 5.5% (93/1836 in the short-course group and 105/1757 in the long-course group). There was no statistically significant difference in the all-cause mortality between two groups (OR = 1.10; 95% CI, 0.82 to 1.48; P = 0.52; Chi² = 7.57; I² = 34%) (Fig. 2). A funnel plot was used to assess the publication bias (Fig. 3).

3.3. Secondary outcomes
3.3.1. Source control.
Three of included studies were analyzed to assess the source control. There was no statistically significant difference in the source control between two groups (OR = 0.82; 95% CI, 0.61 to 1.10; P = 0.18; Chi² = 2.68; I² = 25%) (Fig. 4).

3.3.2. Relapse.
Three of included studies were analyzed to assess the relapse. Relapse included recurrence within 3 months, restarting antibiotics for the same infection and relapse of bacteremia. There was no statistically significant difference in the relapse between two groups (OR = 1.20; 95% CI, 0.71 to 2.01; P = 0.49; Chi² = 0.26; I² = 0%) (Fig. 5).

4. Discussion
The optimal duration of treatment for BSI has not been established. Prescribing practices vary widely, and durations of therapy can range from fewer than 7 days to greater than 14 days. The catheter-related BSI guidelines suggest a 7- to 14-day course of therapy for Gram-negative bacteremia [18]. However, these recommendations are largely consensus based and have poor evidence. A national survey of Canadian ID and critical care specialists identified significant
practice variation in the recommended duration of antibiotic treatment for BSI. The most commonly recommended treatment duration for BSI was 14 days, but more than one-half of clinicians recommended shorter treatment durations (usually 7 days or 10 days)[19].

This systematic review and meta-analysis of six studies including 3593 patients compared short(≤ 10 days) and long course(> 10 days) of antibiotic treatment on clinical outcomes in patients with BSI. We found that the all-cause mortality was about 5.5% and we did not identify an increased all-cause mortality among patients treated with shorter durations compared with those treated with longer durations. In addition, we found short course of antibiotic therapy to be non-inferior to long course in terms of source control and relapse. The extensive use of antibiotics worldwide is closely related to the increasing issues of antimicrobial resistance and antibiotic-associated infections [20, 21]. Long-course antibiotic treatment, as used for BSI, plays a critical role in this context. Among patients with suspected bloodstream infections, broad-spectrum antibiotics must be initiated empirically because early appropriate empiric treatment is associated with improved survival [22, 23]. Due to the rising prevalence of resistant organisms, the tailoring or de-escalation of these empiric regimens is not possible even when blood culture and susceptibility results become available. Patients must then remain on broad-spectrum agents for their full treatment course[24]. Therefore, decreasing the duration of antibiotic treatment to the bare minimum required to treat infections is a reasonable approach to reduce the prevalence of resistance[25]. Of course, it is important to evaluate the efficacy of short-course antimicrobial therapy to avoid treatment failure and recurrence.

Shorter courses of antibiotics may reduce drug-related adverse events, duration of hospitalization, emergence of antibacterial resistance and superinfections, including fungal and Clostridium difficile infection[26]. When judging of duration of antibiotic treatment, there is this second time point at 5–7 days. The decision of escalation/de-escalation/no change or dose adjustments should be taken after 2–3 days when microbiological specimens became available[27]. The effectiveness of therapy should be assessed after one week of treatment on clinical and microbiological resolution of the infection. This will include defervescence and resolution of organ failures and shock, negative subsequent cultures, the absence of endocarditis or metastatic sites of infection and no implanted prosthesis which are all required to define an uncomplicated infection [28]. Problems with source control and/or superinfections at the source will also uncover around that time point. If those are resolved and the pathogen or the source is not specifically requiring extended treatments antibiotic therapy can be safely stopped.

Up to 30–50% of antimicrobial use in most hospitals is inappropriate, with the most common culprit being an excessive duration of therapy[29]. Shorter durations of therapy have been explored for a number of infectious diseases and have been shown to be equally efficacious compared with longer courses of therapy. Appropriate use of antibiotics includes a variety of strategies, such as generating hospital antibiograms, encouraging the use of narrow spectrum antibiotics when feasible, and facilitating the transition from IV to oral antibiotic therapy reducing the need for central line placement[6]. Reducing treatment length in BSI could induce earlier discharge from the hospital, decreased risk of hospital-acquired infections, decreased risk of severe adverse events, and an increased quality of life. Additionally, from a national and international perspective, decreasing the consumption of antibiotics will play an important role in preventing resistance development and secure future antimicrobial treatment[30].

Our meta-analysis has several limitations. First, the number of included studies is small. Further randomized clinical studies should be conducted in order to confirm the results. Second, many of the secondary outcomes such as source control or relapse were not included in all of the studies examined in this meta-analysis. Third, there was still substantial heterogeneity among the included studies. Very heterogeneous populations were included in both prospective and retrospective studies. In addition, definitions of short and long course of antibiotic treatment were widely different among included studies which supposed a limitation to interpret results. Therefore, our findings should be interpreted with caution.

5. Conclusion

Short course of antibiotic treatment is not associated with either an increased risk of mortality or an increased odds of relapse compared with longer antibiotic treatment course for BSI. Furthermore, short course of antibiotic therapy is non-inferior to long course in terms of source control. Further large-scale RCTs are still required to determine the effectiveness and appropriate duration of antibiotic therapy of BSI.

Key Messages

- Short course(≤ 10 days) of antibiotic treatment is not associated with either an increased risk of mortality or an increased odds of relapse compared with longer antibiotic treatment course for BSI.
- Short course of antibiotic therapy is non-inferior to long course in terms of source control.
- Further large-scale RCTs are still required to determine the effectiveness and appropriate duration of antibiotic therapy of BSI.

Abbreviations

BSI: Bloodstream infection; IDSA: Infectious Diseases Society of America; RCTs: Randomized controlled trials; ICUs: Intensive care units; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; NOS: Newcastle-Ottawa Scale; OR: Odds ratio; CI: Confidence interval

Declarations

Acknowledgements
Funding

This work was supported by the Liquid Therapy Research Fund of China Primary Health Care Foundation.

Availability of supporting data

All data generated or analyzed during this study are included in this published article.

Authors' contributions

YL searched the scientific literature and drafted the manuscript. JY contributed to conception, design and data interpretation. JG helped to collect the data and performed statistical analyses. DZ contributed to conception, design, data interpretation, manuscript revision for critical intellectual content and supervision of the study. All authors read and approved the manuscript.

Ethical Approval and Consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Authors' information

Department of Intensive Care Unit The First Hospital of Jilin University Changchun, Jilin, 130021 China

Corresponding author: Dong Zhang. Email: zhangdong21245@sina.com

References

1. Timsit JF, Ruppé E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020;46(2):266-84.

2. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000;118(1):146-55.

3. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis. 2004;38(2):284-8.

4. Timbrook TT, Morton JB, McConeghy KW, Caffrey AR, Mylonakis E, LaPlante KL. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017;64(1):15-23.

5. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. Crit Care. 2011;15(6):R267.

6. Sweeney DA, Kalil AC. Choosing the Duration of Therapy for Bacteremia: Keep Calm and Work With Your Infectious Disease and Antibiotic Stewardship Colleagues. Crit Care Med. 2016;44(2):439-40.

7. Daneman N, Rishu AH, Xiong W, Bagshaw SM, Cook DJ, Dodek P, Hall R, Kumar A, Lamontagne F, Lauzier F, Marshall JC, Martin CM, McIntyre L, Muscedere J, Reynolds S, Stelfox HT, Fowler RA; Canadian Critical Care Trials Group. Duration of Antimicrobial Treatment for Bacteremia in Canadian Critically Ill Patients. Crit Care Med. 2016;44(2):256-264.

8. Mermel LA, Allison M, Bouza E, Craven DE, Flynn R O’Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009 Jul 1;49(1):1-45.

9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Open Med. 2009;3(3):e123-30.

10. Wells GA, Shea B, O’connell D, et al. The Newcastle-Ottawa Scale(NOS) for assessing the quality of non-randomized studies in meta-analysis. Appl Eng Agric. 2014;18:727-34.
11. Biggerstaff BJ, Jackson D. The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis. Stat Med. 2008;27(29):6093-110.

12. Havey TC, Fowler RA, Pinto R, Elligsen M, Daneman N. Duration of antibiotic therapy for critically ill patients with bloodstream infections: A retrospective cohort study. Can J Infect Dis Med Microbiol. 2013;24(3):129-137.

13. Nelson AN, Justo JA, Bookstaver PB, Kohn J, Albrecht H, Al-Hasan MN. Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections. Infection. 2017;45(9):613-620.

14. Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, Tolomeo P, Wise J, Tamma PD; Antibacterial Resistance Leadership Group. Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort. Clin Infect Dis. 2018;66(2):172-177.

15. Giannella M, Pascale R, Toschi A, Ferraro G, Graziano E, Furi F, Bartoletti M, Tedeschi S, Ambretti S, Lewis RE, Viale P. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clin Microbiol Infect. 2018;24(10):1077-1083.

16. Sousa A, Pérez-Rodriguez MT, Suárez M, Val N, Martinez-Lamas N, Nodar A, Longueira R, Crespo M. Short- versus long-course therapy in gram-negative bacilli bloodstream infections. Eur J Clin Microbiol Infect Dis. 2019;38(5):851-857.

17. Lee CC, Hsieh CC, Yang CY, Hong MY, Lee CH, Tang HJ, Ko WC. Short versus long duration antimicrobial treatment for community-onset bacteraemia: A propensity score matching study. Int J Antimicrob Agents. 2019;54(2):176-183.

18. Corona A, Bertiloni G, Ricotta AM, et al. Variability of treatment duration for bacteraemia in the critically ill: a multinational survey. J Antimicrob Chemother. 2003;52:849-852.

19. Daneman N, Shore K, Pinto R, Fowler R. Antibiotic treatment duration for bloodstream infections in critically ill patients: a national survey of Canadian infectious diseases and critical care specialists. Int J Antimicrob Agents. 2011;38(6):480-485.

20. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365(9459):579-87.

21. Lessa FC, Mu Y, Bamberger WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-34.

22. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. Antimicrob Agents Chemother. 2010;54(11):4851-63.

23. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589-96.

24. Harris PNA, Tambyah PA, Lye DC, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: A randomized clinical trial. JAMA. 2018;320(10):984-94.

25. Rice LB. The Maxwell Finland lecture: for the duration-rational antibiotic administration in an Era of antimicrobial resistance and Clostridium difficile. Clin Infect Dis. 2008;46:491-496.

26. Corey GR, Stryjewski ME, Everts RJ. Short-course therapy for bloodstream infections in immunocompetent adults. Int J Antimicrob Agents 2009; 34: S47-51.

27. Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, Tacey M, Timsit JF, Leone M, Zahar JR, De Waele JJ. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis. 2016;62:1009-1017.

28. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18-e55.

29. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-177.

30. Thorlacius-Ussing L, Andersen CO, Frimodt-Møller N, Knudsen IJD, Lundgren J, Benfield TL. Efficacy of seven and fourteen days of antibiotic treatment in uncomplicated Staphylococcus aureus bacteremia (SAB7): study protocol for a randomized controlled trial. Trials. 2019;20(1):250.

Figures
Figure 1
Flow chart of literature selection.

Figure 2
Forest plot for all-cause mortality.
Figure 3
Funnel plot for all-cause mortality.

| Study or Subgroup     | Short course | Long course | Odds Ratio |
|-----------------------|--------------|-------------|------------|
|                       | Events       | Total       |            | M-H, Fixed, 95% CI |
| Chotprasitsakul 2018  | 382          | 385         | 1.34       | [0.30, 6.01] |
| Giannella 2018        | 100          | 124         | 0.76       | [0.56, 1.00] |
| Nelson 2017           | 115          | 282         | 2.45       | [0.54, 11.10] |
| Total (95% CI)        | 928          | 1109        | 0.82       | [0.61, 1.10] |

Total events: 597 for short course, 787 for long course

Heterogeneity: Chi^2 = 2.68, df = 2 (P = 0.26); I^2 = 25%
Test for overall effect: Z = 1.33 (P = 0.18)

Figure 4
Forest plot for source control.

| Study or Subgroup     | Short course | Long course | Odds Ratio |
|-----------------------|--------------|-------------|------------|
|                       | Events       | Total       |            | M-H, Fixed, 95% CI |
| Giannella 2018        | 23           | 19          | 1.23       | [0.66, 2.30] |
| Havey 2013            | 1            | 4           | 0.68       | [0.07, 6.50] |
| Sousa 2018            | 7            | 8           | 1.26       | [0.45, 3.54] |
| Total (95% CI)        | 608          | 715         | 1.20       | [0.71, 2.01] |

Total events: 31 for short course, 31 for long course

Heterogeneity: Chi^2 = 0.26, df = 2 (P = 0.88); I^2 = 0%
Test for overall effect: Z = 0.68 (P = 0.48)

Figure 5
Forest plot for relapse.